The global obesity treatment market size is expected to reach USD 27.10 billion by 2028 at a CAGR of 15.7%, according to a new report by Reports and Data. One of the key parameters driving market revenue growth is rising prevalence of obesity due to sedentary lifestyles, unhealthy eating habits, and lack of physical activity. The global market growth is further bolstered by increasing commercial availability of weight-management programs, rising demand for technologically enhanced weight-loss devices and equipment, and rise in government initiatives undertaken to promote awareness about obesity and its adverse health outcomes. Furthermore, growing trends of health and fitness such as gym culture, increasing cosmetic concerns, especially among millennials, increasing inclination towards weight-loss surgeries, and rising healthcare expenditure create market growth opportunities.

Obesity is a medical condition that results from an increase in the size of fat cells in the body. This condition can lead to a variety of health issues, including diabetes, cardiovascular disease, high blood pressure, and several types of cancer. Common causes of obesity include inadequate sleep, a sedentary lifestyle, and excessive consumption of unhealthy foods. Treatment for obesity typically involves lifestyle changes such as adopting a healthy diet and engaging in regular physical activity. These changes can help manage the condition and reduce the risk of obesity-related health problems. In more severe cases, healthcare professionals may recommend specific weight-loss procedures or medications that have been approved by the FDA. Some of the FDA-approved drugs for weight loss include orlistat (Xenical, Alli), naltrexone-bupropion (Contrave), phentermine-topiramate (Qsymia), semaglutide (Wegovy), and liraglutide (Saxenda).

Get a sample copy of the Obesity Treatment Market report, visit @ https://www.reportsanddata.com/download-free-sample/1480

Some Key Highlights in the Report:

• Based on surgery type, the Biliopancreatic Diversion with Duodenal Switch (BPD/DS) segment is the leading segment, with the highest revenue share in the global obesity treatment market in 2020. Increasing prevalence of obesity-related health issues such as high blood pressure, type 2 diabetes, and other medical problems and growing preference for surgical procedures are expected to bolster this segment’s growth in the coming years.
• Based on drug type, the combination drugs segment reached the largest market share in 2020. Surging prevalence of obesity worldwide and introduction of effective combination therapies for weight management fuel this segment’s growth.
• North America accounted for the largest revenue share of 53% in the global obesity treatment market in 2020. Easy availability of minimally invasive procedures, increasing investments in technological innovations, and rise in research & development activities are the key factors driving the North America market growth. The Asia Pacific market is expected to register the highest CAGR of 18% during the forecast period. Growing awareness about the unfavorable health impacts of obesity, advancing healthcare infrastructure, and growing medical tourism are projected to boost market growth in this region.
• The leading players in the global obesity treatment market include Medtronic, Ethicon (subsidiary of Johnson & Johnson), Cousin Biotech, EnteroMedics, Inc., and USGI Medical, Inc. VIVUS, Inc., Arena Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, and Allergan Plc.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/1480

For the purpose of this report, the global obesity treatment market is segmented on the basis of surgery type, medication type, end-use, and region:

Surgery Type Outlook (Revenue, USD Billion; 2020-2028)

• Biliopancreatic diversion with Duodenal Switch (BPD/DS)
• Adjusting gastric Banding
• Roux-en-Y Gastric Bypass
• Sleeve gastrectomy
• Endoscopic Procedures

Drug Type Outlook (Revenue, USD Billion; 2020-2028)

• Appetite suppressants
• Combination drugs
• Malabsorption
• Satiety drugs

End-use (Revenue, USD Billion; 2020-2028)

• Clinics
• Hospitals
• Beauty institutions
• Others

Regional Outlook (Revenue, USD Billion; 2020-2028)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • BENELUX
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of the Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Rest of the Middle East & Africa

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/1480

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Browse for more reports: